SLC25A4 and Mitochondrial myopathy: They provide evidence that pharmacological strategies aimed at boosting mitochondrial biogenesis, as well as genetic therapies based on AOX, could be effective treatments for mitochondrial myopathies and other human diseases that are associated with ANT deficiency.